The estimated Net Worth of Jeff Baxter is at least $1.42 Milión dollars as of 30 September 2019. Mr. Baxter owns over 150,000 units of VBI Vaccines stock worth over $42,578 and over the last 8 years he sold VBIV stock worth over $0. In addition, he makes $1,379,630 as President, Chief Executive Officer a Director at VBI Vaccines.
Sign up
Mr. Baxter VBIV stock SEC Form 4 insiders trading
Jeffrey has made over 11 trades of the VBI Vaccines stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of VBIV stock worth $75,000 on 30 September 2019.
The largest trade he's ever made was buying 150,000 units of VBI Vaccines stock on 30 September 2019 worth over $75,000. On average, Jeffrey trades about 13,638 units every 27 days since 2016. As of 30 September 2019 he still owns at least 608,255 units of VBI Vaccines stock.
You can see the complete history of Mr. Baxter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Baxter biography
Jeffrey Royston Baxter serves as President, Chief Executive Officer, Director of the Company. Mr. Baxter has served as our President, Chief Executive Officer and as a member of our Board since May 2016. Since July 2014, he has served as the President, Chief Executive Officer and a director of VBI Vaccines (Delaware) Inc. (formerly Paulson Capital (Delaware) Corp.), a Delaware corporation and a wholly-owned subsidiary of the Company (“VBI DE”). Since September 2009, Mr. Baxter has also served as Chief Executive Officer and a member of the board of directors of VBI DE’s wholly-owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“VBI US”). Previously, he was a managing partner for the venture capital firm, The Column Group. Until July of 2006, Mr. Baxter was Senior Vice President, R&D Finance and Operations, of GlaxoSmithKline Biologicals SA, a company registered in the UK (“GSK”). In addition to serving on our Board, Mr. Baxter currently serves as a director of ChromaDex Corporation (NASDAQ: CDXC), which serves dietary supplement, food, beverage, skin care and pharmaceutical markets. In his 19 years of pharma experience, he has held line management roles in finance, commercial, manufacturing and IT and the office of the CEO. His most recent position in R&D included responsibility for finance, pipeline resource planning and allocation, business development, deal structuring and SROne (GSK’s in-house $125 million venture capital fund). He also chaired GSK’s R&D Operating Board. Prior to GSK, he worked at Unilever and British American Tobacco. Mr. Baxter was educated at Thames Valley University and is a Fellow of the Chartered Institute of Management Accountants (“FCMA”).
What is the salary of Jeffrey Baxter?
As the President, Chief Executive Officer a Director of VBI Vaccines, the total compensation of Jeffrey Baxter at VBI Vaccines is $1,379,630. There are no executives at VBI Vaccines getting paid more.
How old is Jeffrey Baxter?
Jeffrey Baxter is 58, he's been the President, Chief Executive Officer a Director of VBI Vaccines since 2016. There are 9 older and 9 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.
What's Jeffrey Baxter's mailing address?
Jeff's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.
Insiders trading at VBI Vaccines
Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv a Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.
What does VBI Vaccines do?
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
What does VBI Vaccines's logo look like?
Complete history of Mr. Baxter stock trades at Chromadex Corp a VBI Vaccines
VBI Vaccines executives and stock owners
VBI Vaccines executives and other stock owners filed with the SEC include:
-
Jeffrey Baxter,
President, Chief Executive Officer, Director -
Jeffery R. Baxter F.C.M.A., FCMA,
Pres, CEO & Director -
Francisco Diaz-Mitoma,
Chief Medical Officer -
David Anderson,
Chief Scientific Officer -
Jeffrey R. Baxter F.C.M.A., FCMA,
Pres, CEO & Director -
Steven Gillis,
Independent Chairman of the Board -
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.,
Chief Medical Officer -
Blaine Mckee,
Independent Director -
Dr. David Evander Anderson,
Chief Scientific Officer -
Joanne Cordeiro,
Independent Director -
Michel Wilde,
Independent Director -
Christopher McNulty,
CFO & Head of Bus. Devel. -
Nicole Anderson,
Investor Relations -
Damian Braga,
Independent Director -
Avi Mazaltov,
Global Head of Manufacturing and SciVac General Manager -
Nell Beattie,
Chief Business Officer -
Christopher McNulty,
Chief Financial Officer and Head of Business Development, Director -
Avi Mazaltov,
Global Head of Manufacturing & GM of SciVac -
Nell Beattie,
Chief Bus. Officer -
T. Adam Buckley,
Sr. VP of Bus. Devel. -
Misha Nossov,
Sr. VP of Market Access & Commercial -
Athena Kartsaklis,
Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer -
Scott Requadt,
Director -
Catherine Eckenswiller,
Contracts and IP Counsel -
Sam Chawla,
Director -
Egidio Nascimento,
Chief Financial Officer -
Adam Logal,
Director -
Jeff Baxter,
CEO, President -
T. Adam Buckley,
VP, Business Development -
Steven D Rubin,
Director -
Advisors Llcperceptive Life...,
-
Health, Inc. Opko,
10% owner -
Tomer Kariv,
Director -
Athena Kartsaklis,
SVP Finance, CCO -
Vaughn B Himes,
Director -
Linda Bain,
Director -
John Robert Dillman,
Chief Commercial Officer